hcp-targeting
(6)
OptimizeRx Put Pharma Ads in the Doctor's Office. Then It Paid $95 Million to Follow the Patient Home
The company started with copay coupons inside prescribing software. Now its bigger wager is that pharma marketing works best when the patient on the sofa and the clinician at the screen receive coordinated messages at the moment a treatment decision is forming.
Swoop Built the Patient Target. Then It Bought the Patient Journey.
Swoop spent a decade helping drug marketers find the right audience. Its next act is harder: connecting ads, patient communities and prescription fulfillment without turning health privacy into collateral damage.
DeepIntent Survived the DSP Winter - Then Taught Pharma Ads to Count Prescriptions, Not Clicks
The New York ad-tech company nearly ran out of road when venture funding for new DSPs froze. A decade later, it sells pharma marketers something the open web rarely offers: a way to connect media spend with clinical outcomes.
AcuityMD
AcuityMD is a Boston-based commercial intelligence platform built specifically for the medical device (MedTech) industry. It translates large volumes of healthcare claims and procedure data into intuitive workflows, AI-powered insights, and recommendations that help medical device sales and marketing teams find high-value physicians and care sites, size and segment markets, manage territories, and accelerate product adoption. Founded in 2019 by former MedTech and consulting operators, the company serves hundreds of device makers - including a majority of the largest MedTech firms - and raised an $80M Series C in 2026 at a near-$1B valuation.
Verix
Verix is a Santa Clara-based software company that builds Tovana, an AI-powered commercial optimization platform for pharmaceutical and life sciences companies. Tovana unifies fragmented commercial data - prescription records, lab results, demographics, and digital marketing signals - and layers predictive modeling, GenAI, and automation on top so brand and field teams can decide the next best action, find the right patients, target the right physicians, and forecast more accurately. Its no-code architecture and pre-built connectors let most deployments go live in 4-8 weeks, and the platform is used by global drugmakers including Bayer, Novartis, GSK, Roche, and Kyowa Kirin.
Doron Aspitz
Doron Aspitz is the President and CEO of Verix, a Santa Clara-based AI platform that helps pharmaceutical companies optimize their commercial operations through predictive analytics, HCP targeting, and GenAI-powered decision intelligence. A serial entrepreneur with 20+ years in technology leadership, he previously co-founded Blue Pumpkin Software - a workforce management company acquired by Witness Systems for ~$75 million in 2005. At Verix, he has built the Tovana platform, now trusted by global pharma giants including Bayer, Novartis, Roche, and GSK, bringing AI-driven commercial intelligence to the complex world of drug commercialization.